Ebola Virus

NIH begins human Ebola vaccine trial using Biojector 2000

Published in Vaccine Weekly, January 7th, 2004

Bioject Medical Technologies, Inc., (BJCT), a developer of needle-free drug delivery systems, announced that the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, recently began its first human trial of a vaccine to prevent Ebola infection utilizing the Biojector 2000 (B-2000).

The B-2000 is a needle-free injection system that is powered by a compressed gas system and is the only device being utilized in the study.

Earlier this year, Bioject had entered into a services and supply subcontract with SAIC-Frederick, Inc., a subsidiary of Science Applications...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-01-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry